Compare · DGX vs LH
DGX vs LH
Side-by-side comparison of Quest Diagnostics Incorporated (DGX) and Labcorp Holdings Inc. (LH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DGX and LH operate in Medical Specialities (Health Care), so they compete in similar markets.
- DGX is the larger of the two at $26.23B, about the same size as LH ($26.06B).
- Over the past year, DGX is up 33.4% and LH is up 19.9% - DGX leads by 13.4 points.
- DGX has been more active in the news (13 items in the past 4 weeks vs 8 for LH).
- Both have 25 recent analyst ratings on file.
- Company
- Quest Diagnostics Incorporated
- Labcorp Holdings Inc.
- Price
- $237.70-0.16%
- $321.23+0.67%
- Market cap
- $26.23B
- $26.06B
- 1M return
- +14.43%
- +16.06%
- 1Y return
- +33.35%
- +19.92%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 13
- 8
- Recent ratings
- 25
- 25
Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Latest DGX
- Bacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest Diagnostics
- SVP & Chief Commercial Officer Delaney Mark E sold $376,288 worth of shares (1,600 units at $235.18) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 10,335 units (SEC Form 4)
- SVP, Clinical Solutions Kuppusamy Karthik increased direct ownership by 0.27% to 13,557 units (SEC Form 4)
- Director Carter Robert B increased direct ownership by 0.29% to 3,864 units (SEC Form 4)
- Director Gregg Vicky B was granted 72 shares, increasing direct ownership by 0.39% to 18,386 units (SEC Form 4)
- SVP for Diagnostic Services Plewman Patrick increased direct ownership by 0.30% to 15,293 units (SEC Form 4)
- Director Main Timothy L increased direct ownership by 0.09% to 22,460 units (SEC Form 4)
- Executive Vice President & CFO Samad Sam was granted 102 shares, increasing direct ownership by 0.31% to 33,478 units (SEC Form 4)
- Director Lassiter Wright Iii increased direct ownership by 0.06% to 10,323 units (SEC Form 4)
- SVP & Chief Commercial Officer Delaney Mark E increased direct ownership by 0.29% to 11,935 units (SEC Form 4)
Latest LH
- Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma
- EVP, Chief Marketing Officer Summy Amy B. sold $283,428 worth of shares (924 units at $306.74), decreasing direct ownership by 12% to 6,956 units (SEC Form 4)
- SEC Form 10-Q filed by Labcorp Holdings Inc.
- SVP, Chief Accounting Officer Wilkinson Peter J sold $439,107 worth of shares (1,420 units at $309.23) and exercised 1,338 shares at a strike of $209.25, decreasing direct ownership by 4% to 1,770 units (SEC Form 4)
- Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer
- Labcorp Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Labcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidance
- Labcorp Launches Marker by Labcorp™ Genetic Health Panel, Expanding Consumer Access to Hereditary Genetic Risk Testing
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Legal Officer Kyle Kathryn W converted options into 256 shares, covered exercise/tax liability with 73 shares and sold $26,329 worth of shares (92 units at $286.19) as part of a pre-agreed trading plan, increasing direct ownership by 2% to 3,904 units (SEC Form 4) (for withholding tax)